|
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide |
Apr 2020 |
Blood Advances |
Aplastic Anemia |
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Alcohol use is not a significant contributor to myelodysplastic syndromes |
Apr 2020 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
|
Targeting TP53 Mutations in Myelodysplastic Syndromes |
Apr 2020 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
|
Evolving therapies for lower-risk myelodysplastic syndromes |
Apr 2020 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities |
Mar 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
Mar 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
Jan 2020 |
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
Jan 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
Jan 2020 |
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
